tbuckley/cabot-search huggingface dataset:
Abstract 212: Are there cell cycle-dependent variations in cadherin-mediated cell adhesion.
Authors: Maria Cimpean, Yangjinqi Yu, Brenna Laperle, Edie Corey, William A. Thomas
Journal: Cancer Research (2013)

Abstract Cell adhesion makes possible the development of tissues and organs. It has thus been an important topic in biomedical research, cancer research in particular. One method used to quantify cell adhesion, the dual pipette assay, has shown persistent variability in the force required to separate adherent cells despite efforts to minimize variability through strict protocols and assay automation. We are using FUCCI (fluorescence ubiquitination cell cycle indicator) to determine if cell-cycle dependent changes might account for the observed variability in separation force. The FUCCI technique involves antiphase oscillating proteins that mark the cell-cycle transitions with corresponding fluorescent probes. Initial comparison of fluorescence distributions in aggregated and unaggregated FUCCI E cad cells showed no preferential accumulation in aggregates of cells in a particular stage of the cell cycle. Work continues to improve the resolution and reproducibility of the tests. Citation Format: Maria Cimpean, Yangjinqi Yu, Brenna Laperle, Edie Corey, William A. Thomas. Are there cell cycle-dependent variations in cadherin-mediated cell adhesion. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 212. doi:10.1158/1538-7445.AM2013-212 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Abstract 5255: Methionine restriction limits prostate tumor cell proliferation
Authors: Emma H. Allott, Xiaohu Tang, Elizabeth M. Masko, Alexis Gaines, Michael R. Abern, Jen-Tsan A. Chi, Stephen J. Freedland
Journal: Cancer Research (2012)

Abstract Introduction: Methionine restriction has been shown to have growth inhibitory effects in a number of tumor cell lines in vitro. Methionine restriction has previously been demonstrated to slow PC-3 prostate tumor cell growth in vivo, however not at dietary levels tolerable to humans. Up to 90% dietary methionine restriction has been demonstrated to be both tolerable and safe in a preliminary human clinical trial. We hypothesized that 80%-90% methionine restriction could limit prostate tumor cell growth in vitro and in vivo. Methods: We reduced methionine levels by 40%, 80%, 90% and 100% in prostate cancer cell lines in vitro, relative to standard RPMI medium. Cell proliferation and viability were measured using MTS and trypan blue assays, respectively. PC-3 cells were grafted into a xenograft nude mouse model and animals were randomized to standard chow, 80% or 90% methionine restricted diets. Plasma methionine levels were measured before and after the dietary intervention. Tumor volume was measured throughout the study and mice were sacrificed when tumors reached 1000 mm3. Results: Methionine restriction exerted a dose and time-dependent effect on PC-3 tumor cell proliferation and viability in vitro. Methionine restriction of 80% and 90% for a period of 6 days reduced PC-3 tumor cell line proliferation by 20% and 40%, respectively, as measured by MTS assay (p&amp;lt;0.0001). Following 6 days of 80% and 90% methionine restriction, PC-3 cell viability was reduced by 10% and 15%, respectively. We are currently awaiting results from our in vivo study which is underway. Discussion: Methionine restriction slows prostate tumor cell line growth and reduces cell line viability in vitro. Based upon these in vitro results we hypothesize that an 80% - 90% methionine restricted diet will slow tumor growth in vivo, and we await the results of this dietary intervention in mice. Methionine restriction at this clinically relevant level which is tolerable and safe to humans may have the potential to slow tumor growth in prostate cancer patients; however more preliminary studies are needed in order to establish whether 80%-90% methionine restriction actually does slow tumor growth in vivo and if so to understand the mechanisms by which this occurs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5255. doi:1538-7445.AM2012-5255
Tiotropium for Asthma — Promise and Caution
Authors: Elisabeth H. Bel
Journal: New England Journal of Medicine (2012)

Anticholinergic agents have been available for the treatment of airways obstruction for many decades. For patients with chronic obstructive pulmonary disease (COPD), many practitioners believe that these drugs have become the bronchodilator of choice. For patients with asthma, anticholinergic agents are less popular, probably because of their slower onset of action as a reliever medication and their generally inferior effect on lung function and symptoms, as compared with inhaled beta-agonists.Not surprisingly, long-acting beta-agonists (LABAs) in combination with inhaled glucocorticoids have become standard treatment for patients with asthma that is poorly controlled while receiving inhaled glucocorticoids alone. Although this treatment . . .
Colonoscopy complicated by arterial avulsion and retroperitoneal hemorrhage
Authors: K. Langer, S. Kriegler, M. Moser
Journal: Endoscopy (2011)

A 77-year-old woman with a past surgical history of hysterectomy presented to the Emergency Department with increasing lower abdominal and back pain. A routine screening colonoscopy had been performed 8 hours previously; the endoscopist had noted that the colon was tortuous, however no abnormality had been seen.
Case 1-2015
Authors: Beverly Moy, Michelle C. Specht, Michael Lanuti, Elizabeth A. Rafferty, Melinda F. Lerwill
Journal: New England Journal of Medicine (2015)

In a 66-year-old woman, enlarged lymph nodes were seen on routine breast imaging. She had received a diagnosis of ductal carcinoma 6 years earlier and had been treated with radiation and chemotherapy, followed by anastrozole. A diagnostic procedure was performed.
INCIDENCE OF LATE CATCH-UP PHENOMENON BETWEEN SIROLIMUS-ELUTING STENT AND EVEROLIMUS-ELUTING STENT DURING 3 YEARS FOLLOW-UP: A PROPENSITY MATCHED STUDY
Authors: Norihiro Kobayashi, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano
Journal: Journal of the American College of Cardiology (2015)
Evaluation of preoperative letrozole treatment to DCIS by MRMammography.
Authors: T Kuwayama, S Nakamura, A Yoshida, H Yagata, K Tsugawa, J Takei, H Tsunoda-Shimizu, K Suzuki
Journal: Cancer Research (2009)

Abstract Abstract #1164 Background:&amp;#x2028; Since ductal carcinoma in situ (DCIS) often spreads diffusely along a lactiferous duct as multicentric lesions, it is generally treated by mastectomy. The response rate to letrozole is approximately 60%, which is relatively high among the preoperative endocrine therapies for invasive cancer, and it enables at least 50% of patients with little chance of saving the breast to actually receive breast-conserving surgery. This study was conducted to determine the value of preoperative endocrine therapy with letrozole for postmenopausal patients with hormone receptor (HR)-positive DCIS.&amp;#x2028; Methods:&amp;#x2028; Postmenopausal women who had been diagnosed with HR-positive DCIS by needle biopsy (Allred score ≥3) were treated with letrozole for 12 weeks. The primary endpoint was the response of target lesions evaluated by MRI based on the RECIST criteria. Patients who had no safety problems, except PD, continued letrozole therapy for up to 24 weeks, and the tumor response after 24 weeks and the rate of breast-conserving surgery were assessed. In addition to RECIST-based evaluation, changes of tumor volume on MRI were examined. Changes of Ki67, bcl-2, ER, and PgR with letrozole therapy were also assessed.&amp;#x2028; Results:&amp;#x2028; Twelve postmenopausal women with DCIS were enrolled, but one patient was excluded because her Allred score was 2. Using by RECIST criteria , the tumor response after 12 weeks was CR in 1 patient and SD in 10 patients. All 6 patients who could be evaluated after 24 weeks showed SD. But the evaluation by tumor volumetoric method, tumor was significantly reduced to an average of 42.2% after 12 weeks compared to before treatment.(p=0.0057) Two patients continued letrozole therapy for longer than 24 weeks. After 24 weeks of therapy, 3 patients underwent breast-conserving surgery and no mastectomies were performed. Pathological findings showed that the spread of tumor was likely to that of preoperative MRMammogrraphy. PgR was significantly reduced by letrozole therapy. There were no safety problems was not observed.&amp;#x2028; Discussion:&amp;#x2028; The efficacy of preoperative treatment with letrozole for 12 weeks was verified in postmenopausal patients with HR-positive DCIS. Two patients received breast-conserving surgery after letrozole therapy that had been considered impossible before treatment. Evaluation of treatment to DCIS using by RECIST criteria is unsutable,but the evaluation by MRMammography is considered to be a suitable method for determining the efficacy of therapy for DCIS. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1164.
REQUIREMENT OF PERMANENT PACEMAKER PLACEMENT AND INCIDENCE OF LEFT BUNDLE BRANCH BLOCK IN PATIENTS UNDERGOING TRANSCATHETER AORITC VALVE IMPLANTATION: A META-ANALYSIS OF EDWARDS SAPIEN VALVE VERSUS MEDTRONIC COREVALVE
Authors: Hemang B. Panchal, Neil Barry, Samit Bhatheja, Vijay Ramu, Timir Paul, Steven Lavine
Journal: Journal of the American College of Cardiology (2015)
Lymphoscintigraphy of Isolated Chylopericardium
Authors: TETSURO YAMAZAKI, SHIN MARUOKA, SHOKI TAKAHASHI, KIYOHIKO SAKAMOTO
Journal: Clinical Nuclear Medicine (1996)

Isolated chylopericardium is a rare condition in which chylous effusion accumulates in the pericardial sac without pleural effusion. Pedal lymphoscintigraphy with Tc-99m HSA in a 21-year-old woman demonstrated abnormal lymphatic flow in the mediastinum and accumulation of the tracer in the pericardial region. Lymphoscintigraphy can directly visualize influx of the chyle in the pericardial sac.
EXERCISE INTENSITY AND CENTRAL BLOOD PRESSURE
Authors: Jae Hyoung Park, Jong-Ho Kim, Ji-Hyun Choi, Seung-Cheol Choi, Hyo-Jung Nam, Hyung Joon Joo, Chul-Min Ahn, Soon Jun Hong, Cheol Woong Yu, Do-Sun Lim
Journal: Journal of the American College of Cardiology (2014)
FRI0134 Increased progression of carotid intima media thickness in thyroid peroxidase antibody positive rheumatoid arthritis patients
Authors: H. Raterman, A. E. Voskuyl, S. Simsek, M. Schreurs, I. V. Hoogstraten, M. Peters, V. V. Halm, B. Dijkmans, P. Lips, W. Lems, M. Nurmohamed
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Coexistence of autoimmune disorders was recently demonstrated for rheumatoid arthritis (RA) and hypothyroidism, and, interestingly, this coexistence amplifies the elevated cardiovascular risk in RA. Autoimmune hypothyroidism is characterised by the presence of thyroid peroxidase antibodies (TPOabs). Whether TPOabs are associated with increased CVD risk has not been studied extensively. <h3>Objectives</h3> The aim of this study was firstly to determine the prevalence of TPOabs in RA and secondly to assess whether their presence was associated with cardiovascular disease (CVD). Moreover, this study explored whether TPOabs were related to disease specific parameters in RA patients. <h3>Methods</h3> Data from the CARRÉ Study, an ongoing study investigating cardiovascular diseases and its risk factors in RA (n = 353) was used to ascertain the prevalence of TPOabs in RA patients. Additionally, cardiovascular and RA disease characteristics were compared between and cardiovascular and RA parameters were compared between TPOabs positive and negative patients. <h3>Results</h3> TPOabs were present in 47/322 (15%) RA patients and TPOabs were associated with higher TSH levels (p = 0.048). CVD was observed in 22% of TPOabs positive patients compared to 17% of the TPOabs negative patients (p = 0.44). Linear regression analyses revealed a significantly larger progression of carotid Intima Media Thickness (cIMT) in TPOabs positive compared to TPOabs negative patients (p = 0.032). Disease activity scores (DAS28) were higher in TPOabs positive patients compared to TPOabs negative patients (4.4 ± 1.3 vs 3.8 ± 1.4, p = 0.018). A significant lower percentage of the TPOabs positive compared to TPOabs negative RA patients were in a low disease activity state (DAS28 &lt; 3.2), respectively 16% and 32% (OR: 0.36, 95% CI: 014 – 0.88, p = 0.032). <h3>Conclusions</h3> In this study the presence of TPOabs was associated with increased cIMT progression. Moreover, an association between TPOabs and RA disease activitiy was observed. Hence, TPOabs seems to have a role in the amplified CV risk in hypothyroid patients. <h3>Disclosure of Interest</h3> None Declared
A global perspective on the use of aromatase inhibitors in early-stage breast cancer.
Authors: C Jackisch, S Verma
Journal: Cancer Research (2009)

Abstract Abstract #1144 Background: Aromatase inhibitors (AIs) are considered to be the standard of care for the adjuvant treatment of postmenopausal patients with hormone-receptor positive (HR+) early breast cancer (EBC). However, there is a lack of data on the use of these drugs in the non-trial setting and in regional practice around the world.&amp;#x2028; Methods: This survey examined the use of endocrine therapies in breast cancer by physicians in 7 countries. From July 27 to October 8, 2007, 462 physicians in the United States, Germany, the United Kingdom, France, Spain, Italy, and Japan were surveyed, and information was collected via an internet Web site. Data included the physicians' reported activity during the last month, AI profiles, and patient profiles according to treatment stage.&amp;#x2028; Results: Surveyed were 381 oncologists, 14 gynecologists, 36 surgeons, and 31 mammary gland clinicians. Physician perceptions were similar to the actual patient data. Half of all women being treated for breast cancer were HR+ and postmenopausal (less in Japan: 38%), and almost all of those patients (80-95%) were receiving endocrine therapy for the adjuvant treatment of EBC. AIs were the most common hormone agents used in the initial adjuvant setting of postmenopausal women with HR+ EBC across all countries surveyed (55-93%; median 88%). An upfront AI strategy was the most common practice overall, particularly in Japan, the United States, and France (89%, 86%, and 86%, respectively). Initial tamoxifen therapy was used predominantly in Germany (36%), the United Kingdom (51%), and Italy (55%). However, in the United Kingdom and Germany, the intent in nearly half of these patients was to switch to an AI following 2 years of tamoxifen therapy. The rates at which the 3 AIs were prescribed for different types of adjuvant treatment were generally consistent across countries. Guidelines were identified as a major decision-making factor in all countries.&amp;#x2028; Conclusion: There are variations in practice across the surveyed countries despite the presence of international guidelines, eg, the American Society of Clinical Oncology and St. Gallen 2007. These practice trends may reflect the various guidelines in each region. Differences in treatment are particularly seen in Europe, which may reflect the number of varying guidelines and less descriptive nature of the guidelines. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1144.
Managing Wastewater from Fracking, with Robert B. Jackson
Authors: Ashley Ahearn
Journal: Environmental Health Perspectives (2012)

Hydraulic fracturing ("fracking") is a controversial practice used in natural-gas drilling. Fracking makes it much more feasible to free the vast reserves of natural gas locked underground, but the practice comes with concerns that the natural gas boom is proceeding too fast, before we understand the human health impacts. Discussions about fracking and community health typically involve questions about methane contamination of drinking water wells around drill sites. In this podcast, host Ashley Ahearn talks with Robert B. Jackson about another fracking-related water concern: the millions of gallons of contaminated wastewater generated by the process.
White paper puts GPs in the driving seat of the new NHS
Authors: J. Warden
Journal: BMJ (1997)

The British government views its new 10 year plan, outlined this week, as a turning point for the NHS. The white paper The New NHS gives control of most of the NHS budget to GPs and community nurses, writes John Warden 

The new NHS, foreshadowed in the white paper, will build on what has worked and discard what has failed. It is the basis of a 10 year programme of “evolutionary change rather than organisational upheaval.” There will be no return to Labour's old command and control system. But there will be an end to the competitive internal market, introduced by the Conservatives; in its place will be a system of “integrated care” based on partnership driven by performance. The government believes that “what counts is what works.”

Many features of the internal market will survive. For example, the separation between the purchase and provision of hospital care will be retained; cooperation, however, will replace competition. Local doctors, nurses, and health authorities will have new powers to commission services and ensure that the local NHS is built around the needs of patients. Health authorities will have a powerful supervisory role with greater input …
Stat Bite: Prostate Cancer Incidence and Mortality
Authors: B. Miller
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Stat Bite : Prostate Cancer Incidence and Mortality Get access Barry Miller Barry Miller Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 13, 7 July 1993, Page 1023, https://doi.org/10.1093/jnci/85.13.1023 Published: 07 July 1993
Bone Scintigraphy in a Patient With Giant Malignant Solitary Fibrous Tumor of the Pleura
Authors: Long Zhao, JinJun Liu, Qiang Li, Huo-Qiang Wang
Journal: Clinical Nuclear Medicine (2016)

Chest radiograph performed in a 61-year-old woman to evaluate cough showed a large mass in the right lung. On chest CT images, the mass was measured approximately 8.5 cm. Malignancy was considered, and bone scintigraphy was performed to assess possible osseous metastases. The bone scan images demonstrated increased tracer uptake by the lung mass. The mass was surgically resected, and the pathologic examination confirmed the rare diagnosis of a malignancy solitary fibrous tumors of the pleura.
ASSOCIATIONS OF ABNORMAL ANTHROPOMETRY AND DELAYED PUBERTY WITH QUALITY OF LIFE IN YOUNG FONTAN SURVIVORS: A MULTICENTER CROSS-SECTIONAL STUDY
Authors: Shaji C. Menon, Al-Dulaimi Ragheed, Brian McCrindle, David Goldberg, Ritu Sachdeva, Bryan Goldstein, Thomas Seery, Karen Uzark, Anjali Chelliah, Ryan Butts, Heather Henderson, Tiffanie Johnson, Richard Williams
Journal: Journal of the American College of Cardiology (2016)
Children of Mothers with Down's Syndrome
Authors: A. W. Johnston, R. I. Jaslow
Journal: New England Journal of Medicine (1963)

IN only two of the syndromes associated with chromosome abnormalities described in man has fertility been reported. These patients are women with the XXX syndrome or with mongolism. Both events are of considerable interest, for the phenomenon of secondary nondisjunction has been exploited in genetic investigations ever since Bridges1 coined the term in 1916. No detailed account of the children borne to XXX mothers has yet been published. This paper gives the clinical and cytogenetic data on the Lapeer family, consisting of a mother and child, both with mongolism, originally recorded by Rehn and Thomas,2 more recently by Stiles and . . .
Ga-67 Scintigraphy in a Patient with Deep Vein Thrombosis as the Probable Cause of Fever of Unknown Origin
Authors: Hitoya Ohta, Hwnag Moon Moon Hee, Hiroshi Higashiyama, Tsueshi Nakano, Takao Suzuki
Journal: Clinical Nuclear Medicine (2002)

OHTA, HITOYA M.D.,*; MOON HEE, HWANG M.D.,†; HIGASHIYAMA, HIROSHI M.D.,‡; NAKANO, TSUNESHI*; SUZUKI, TAKAO* Author Information
AB0580 Selological responce of the H1N1PDM influenza vaccine in patients with rheumatoid arthritis treated with monoclonal antibody therapy or conventional DMARDS, comparison with healthy adult
Authors: T. Tsuru, M. Suzaki, K. Maeda, H. Nakashima, T. Eto, M. Ishibashi, J. Manabe, K. Terao, S. Irie
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> We investigated the immunogenicity of the vaccine for H1N1pdm influenza, which became a global pandemic in 2009/2010. We reported the vaccination study outcomes based on the patients with rheumatoid arthritis, however we would like to know how much serological response who are exposed to H1N1 pdm, are expected in patients with rheumatoid arthritis under monoclonal antibody therapy, conventional DMARDs compared to healthy adults. <h3>Methods</h3> One hundred twenty-six patients (29 males and 97 females) with rheumatoid arthritis (RA) and thirty healthy volunteer were enrolled. In RA patients, conventional DMARDs, infliximab(INF), etanercept(ETA) and tocilizumab(TCZ) were treated by 59 patients, 27 patients, 18 patients, and 22 patients, respectively. Patients were vaccinated twice in September and October with the H1N1pdm influenza vaccine (Biken). Serum samples were taken prior to vaccination the first (S0) and second (S1) vaccinations, and in the fourth week after the second vaccination (S2), and serum antibody titres were measured using the haemagglutination inhibition (HI) assay. Using these data, we investigated the response rate (increase in HI titre ≥4-fold), seroprotection rate (HI titre ≥1:40), and seroconversion rate (increase in HI titre from pre-vaccination titre &lt;1:10 to post-vaccination HI titre ≥1:40, or a 4-fold increase in post-vaccination titre from a pre-vaccination HI titre ≥1:10). <h3>Results</h3> 1) The response rate at S1/S0 and S2/S0 are 59% and 69% in healthy volunteer, 60% and 74% in pts received DMARDs, 30% and 56% in pts received INF, 53% and 65% in pts treated ETA, and 77% and 76% in pts with TCZ. 2) Seroprotection rate at S1 and S2 are 34% and 45% in healthy volunteer, 40% and 47% in pts received DMARDs, 22% and 37% in pts received INF, 35% and 47% in pts treated ETA, and 50% and 48% in pts with TCZ. 3) Seroconversion rate at S1 and S2 are 55% and 66% in healthy volunteer, 59% and 68% in pts received DMARDs, 37% and 48% in pts received INF, 53% and 65% in pts treated ETA, and 64% and 71% in pts with TCZ. <h3>Conclusions</h3> In this research on the pandemic influenza vaccine, we found no inhibition of immunogenicity in patients receiving tocilizumab compared to healthy volunteer and patients with monoclonal antibody or DMARDs. <h3>Disclosure of Interest</h3> T. Tsuru Consultant for: USB, Employee of: Medical Co.LTA, M. Suzaki Employee of: Medical Co.LTA, K. Maeda: None Declared, H. Nakashima: None Declared, T. Eto Employee of: Medical Co.LTA, M. Ishibashi Employee of: Medical Co.LTA, J. Manabe Employee of: Medical Co.LTA, K. Terao Employee of: ChugaiPharmaceutical Co.,LTD., S. Irie Employee of: Medical Co.LTA
Rapid, multifluorescent TCRG Vγ and Jγ typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations
Authors: E Delabesse, M-L Burtin, C Millien, A Madonik, B Arnulf, K Beldjord, F Valensi, EA Macintyre
Journal: Leukemia (2000)
Genetic Targeting of the Albumin Locus to Treat Hemophilia
Authors: Andrew M. Davidoff, Amit C. Nathwani
Journal: New England Journal of Medicine (2016)

Goals of gene therapy include the integration of the therapeutic gene into the host genome at expression levels sufficient to ameliorate symptoms. Strategies involving the transcriptional machinery of albumin in the liver have proved effective in a mouse model of hemophilia.